enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Hormone receptor positive breast tumor - Wikipedia

    en.wikipedia.org/wiki/Hormone_receptor_positive...

    ER-positive is one of the Receptor statuses identified in the classification of breast cancer.Receptor status was traditionally considered by reviewing each individual receptor (ER, PR, her2) in turn, but newer approaches look at these together, along with the tumor grade, to categorize breast cancer into several conceptual molecular classes [1] that have different prognoses [2] and may have ...

  3. HER2 - Wikipedia

    en.wikipedia.org/wiki/HER2

    HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. But contrary to other members of the ERBB family, HER2 does not directly bind ligand. HER2 activation results from heterodimerization with another ERBB member or by homodimerization when HER2 concentration are high, for instance in cancer. [8]

  4. Triple-negative breast cancer - Wikipedia

    en.wikipedia.org/wiki/Triple-negative_breast_cancer

    Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification (i.e. the tumor is negative on all three tests giving the name triple-negative). [1]

  5. Epidermal growth factor receptor - Wikipedia

    en.wikipedia.org/wiki/Epidermal_growth_factor...

    The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer. [6]

  6. Breast cancer classification - Wikipedia

    en.wikipedia.org/wiki/Breast_cancer_classification

    HER2-low has some HER2 proteins on the cell surface, but not enough to be classified as HER2-positive. [4] Trastuzumab deruxtecan is the first approved therapy by the US Food and Drug Administration (FDA) targeted to people with the HER2-low breast cancer subtype. [4] DNA-based classification.

  7. Breast cancer - Wikipedia

    en.wikipedia.org/wiki/Breast_cancer

    This is an accepted version of this page This is the latest accepted revision, reviewed on 21 December 2024. Cancer that originates in mammary glands Medical condition Breast cancer An illustration of breast cancer Specialty Oncology Symptoms A lump in a breast, a change in breast shape, dimpling of the skin, fluid from the nipple, a newly inverted nipple, a red scaly patch of skin on the ...

  8. Sacituzumab govitecan - Wikipedia

    en.wikipedia.org/wiki/Sacituzumab_govitecan

    Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. [12] Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. [12]

  9. Abemaciclib - Wikipedia

    en.wikipedia.org/wiki/Abemaciclib

    Abemaciclib was approved for the adjuvant treatment of HR+, HER2-, node-positive adjuvant breast cancer at high risk of recurrence in March 2023. [15] [16] As of 2023, abemaciclib was involved in two Phase III clinical trials: The SARC041 study compares abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. [17]